CalciMedica, Inc. stock is down -27.81% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 February’s closed higher than January. 100% of analysts rate it a buy.
CalciMedica, Inc. focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials. GB-401, an implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!